Diabetic Macular Edema Market Analysis

The Global Diabetic Macular Edema Market is estimated to be valued at USD 4.2 Billion in 2024 and is expected to reach USD 6.1 Billion by 2031, growing at a compound annual growth rate (CAGR) of 4.23% from 2024 to 2031.

The market is witnessing positive growth trends over the period. Increasing prevalence of diabetes worldwide along with rise in obese and geriatric population are major factors responsible for the growth of diabetic macular edema market. Accelerated approvals and launches of novel drugs and expanding healthcare infrastructure in emerging markets also support the market expansion. The diabetic macular edema (DME) market is driven by the increasing prevalence of diabetes, leading to a growing number of patients with vision complications. DME is a leading cause of vision loss in diabetic patients, characterized by fluid accumulation in the macula. Key treatments include anti-VEGF therapies such as ranibizumab (Lucentis), aflibercept (Eylea), and corticosteroids like dexamethasone implants. The market is witnessing growth due to advances in these treatments and an aging global population. However, challenges include high costs of therapies, treatment adherence issues, and limited access in developing regions, impacting patient outcomes and market penetration.